PMID- 35301936
OWN - NLM
STAT- MEDLINE
DCOM- 20230810
LR  - 20230810
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 133
IP  - 9
DP  - 2023 Dec
TI  - Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a 
      meta-analysis.
PG  - 1008-1016
LID - 10.1080/00207454.2022.2032045 [doi]
AB  - BACKGROUND: In the present meta-analysis, the efficacy and safety of perampanel 
      (PER) for the treatment of adolescents with epilepsy were assessed. METHODS: 
      Keyword searches were performed in Embase, PubMed, Cochrane Library, Web of 
      Science, EBSCO and CNKI from 1 January 2020 to 10 October 2020. The randomized 
      controlled trials (RCTs) and case-control studies in which PER was compared with 
      other Anti-seizure drugs (ASDs) and/or placebo in children with epilepsy, were 
      considered eligible studies. Odds ratio (OR) with 95% confidence interval (95% 
      CI) for the dichotomous outcome statistic was calculated using a fixed-effects or 
      random-effects model. RESULTS: Three RCTs with a total of 372 adolescents' 
      patients were included in this meta-analysis. Placebo was used as a control in 
      these studies. Compared with placebo, PER showed better efficacy in median 
      seizure frequency reduction from baseline per 28 days (OR = 2.49, 95% CI: 
      1.25-4.96, p = 0.009) and in responder rate (OR = 1.87, 95% CI: 1.15-3.05, 
      p = 0.01); both were considered statistically increased in PER group. Regarding 
      adverse effects (AEs), significant differences between PER and placebo (OR = 
      1.47, 95% CI: 0.92-2.41, p = 0.11) were not found, and the most common AEs of PER 
      were dizziness (24.0%), somnolence (15.9%), headache (11.2%), nasopharyngitis 
      (9.7%), upper respiratory tract infection (7.0%) and aggression (7.0%). 
      CONCLUSION: Based on the results in this study, PER showed better efficacy than 
      placebo therapy in children with epilepsy and the AEs were similar in PER group 
      and placebo group. PER showed good efficacy and a low risk of AEs, and might be a 
      promising medication for the treatment of pediatric epilepsy. In the future, 
      well-designed and large-scale RCTs are necessary to validate the present 
      findings.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Pediatrics, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Shaanxi, China.
FAU - Li, Limin
AU  - Li L
AD  - Department of Pediatrics, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Shaanxi, China.
FAU - Sun, Fei
AU  - Sun F
AD  - Department of Pediatrics, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Shaanxi, China.
FAU - Yang, Yonghua
AU  - Yang Y
AD  - Department of Pediatrics, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Shaanxi, China.
FAU - Liu, Xiaohong
AU  - Liu X
AD  - Department of Pediatrics, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Shaanxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220318
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - H821664NPK (perampanel)
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Humans
MH  - Child
MH  - Adolescent
MH  - Anticonvulsants/adverse effects
MH  - Treatment Outcome
MH  - *Epilepsies, Partial/drug therapy
MH  - *Epilepsy/drug therapy/chemically induced
OTO - NOTNLM
OT  - Epilepsy
OT  - adolescents
OT  - efficacy
OT  - meta-analysis
OT  - perampanel
OT  - safety
EDAT- 2022/03/19 06:00
MHDA- 2023/08/10 06:43
CRDT- 2022/03/18 08:39
PHST- 2023/08/10 06:43 [medline]
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/03/18 08:39 [entrez]
AID - 10.1080/00207454.2022.2032045 [doi]
PST - ppublish
SO  - Int J Neurosci. 2023 Dec;133(9):1008-1016. doi: 10.1080/00207454.2022.2032045. 
      Epub 2022 Mar 18.